E-Qure Inks First Distribution Agreement With Argentinian Firm

E-Qure has signed its first distribution agreement with Argentinian medical device distributor Rubifarm S.A., to market its bio-electrical signal therapy device, a noninvasive therapy for the treatment of chronic wounds. The agreement is effective immediately.

E-Qure, in making the announcement Wednesday, revealed that Rubifarm has put up a minimum electrode purchasing obligation of $50,000 for the first year, eventually rising to a minimum of $1 million after five years.

The agreement also stipulates that devices will be rented out to hospitals and clinics. Rubifarm will sell disposable electrodes on the basis of treatment day need.

E-Qure projects that 400,000 people in Argentina are afflicted with Stage 2 to Stage 4 chronic wounds, such as pressure ulcers, diabetic foot ulcers, venous stasis ulcers and other hard to heal ulcers.

The company is seeking FDA clearance so it can begin marketing in the U.S. as well. — Jason Scott